Gene Therapy for High Grade Glioma: The Clinical Experience

References

• Surveillance. Epidemiology, and end results: cancer stat facts: brain and other nervous system cancer. Internet. 2022.
   Google Scholar
• Björkblom B, Wibom C, Eriksson M, et al. Distinct metabolic hallmarks of WHO classified adult glioma subtypes. Neuro Oncol. 2022 Sep 1;24(9):1454–1468.
   PubMed Web of Science ®Google Scholar
• Galbraith K, Snuderl M. Molecular pathology of gliomas. Surg Pathol Clin. 2021 Sep;14(3):379–386.
   PubMedGoogle Scholar
• Molinaro AM, Taylor JW, Wiencke JK, et al. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019 Jul;15(7):405–417.
   PubMed Web of Science ®Google Scholar
• Pekmezci M, Perry A. Genetic markers in adult high-grade gliomas. Semin Radiat Oncol. 2014 Oct;24(4):235–239.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459–466.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008 Sep 1;26(25):4189–4199.
   PubMed Web of Science ®Google Scholar
• Walker MD, Alexander E Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978 Sep;49(3):333–343.
   PubMed Web of Science ®Google Scholar
• Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007 Apr 12;356(15):1527–1535.
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain tumor cooperative group trial 8001. J Neurosurg. 1989 Jul;71(1):1–9.
   PubMed Web of Science ®Google Scholar
• Nelson DF, Curran WJ Jr., Scott C, et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma–possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the radiation therapy oncology group protocol 8302. Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):193–207.
   PubMed Web of Science ®Google Scholar
• Ali AN, Zhang P, Yung WKA, et al. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol. 2018 Mar;137(1):39–47.
   PubMed Web of Science ®Google Scholar
• Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853–860.
   PubMed Web of Science ®Google Scholar
• Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004 May 1;22(9):1583–1588.
   PubMed Web of Science ®Google Scholar
• Roa W, Kepka L, Kumar N, et al. International atomic energy agency randomized phase iii study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015 Dec 10;33(35):4145–4150.
   PubMed Web of Science ®Google Scholar
• Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012 Sep;13(9):916–926.
   PubMed Web of Science ®Google Scholar
• Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017 Mar 16;376(11):1027–1037.
   PubMed Web of Science ®Google Scholar
• Niyazi M, Brada M, Chalmers AJ, et al. ESTRO-ACROP guideline “target delineation of glioblastomas”. Radiother Oncol. 2016 Jan;118(1):35–42.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. Jama. 2017 Dec 19;318(23):2306–2316.
   PubMed Web of Science ®Google Scholar
• Burri SH, Gondi V, Brown PD, et al. The evolving role of tumor treating fields in managing glioblastoma: guide for oncologists. Am J Clin Oncol. 2018;41(2):191–196.
   PubMed Web of Science ®Google Scholar
• Fu P, Y-S H, Huang Q, et al. Bevacizumab treatment for newly diagnosed glioblastoma: systematic review and meta-analysis of clinical trials. Mol Clin Oncol. 2016;4(5):833–838.
   PubMedGoogle Scholar
• Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1100–1108.
   PubMed Web of Science ®Google Scholar
• Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1373–1385.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020 Jul 1;6(7):1003–1010.
   PubMed Web of Science ®Google Scholar
• Narita Y, Arakawa Y, Yamasaki F, et al. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. Neuro Oncol. 2019 Feb 19;21(3):348–359.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Brenner A, de Groot JF, et al. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro Oncol. 2020 May 15;22(5):705–717.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1–v100.
   PubMed Web of Science ®Google Scholar
• Udaka YT, Packer RJ. Pediatric Brain Tumors. Neurol Clin. 2018 August;36(3):533–556.
   PubMed Web of Science ®Google Scholar
• Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell. 2017;32(4):520–537.e5.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012 Jan 29;482(7384):226–231.
   PubMed Web of Science ®Google Scholar
• Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012 Oct 16;22(4):425–437.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231–1251.
   PubMed Web of Science ®Google Scholar
• Schwark K, Messinger D, Cummings JR, et al. Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: pre-clinical models and precision medicine. Front Oncol. 2022;12:922928.
   PubMed Web of Science ®Google Scholar
• Guerreiro Stucklin AS, Ryall S, Fukuoka K, et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun. 2019 Sep 25;10(1):4343.
   PubMedGoogle Scholar
• Batra V, Sands SA, Holmes E, et al. Long-term survival of children less than six years of age enrolled on the CCG-945 phase III trial for newly-diagnosed high-grade glioma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014 Jan;61(1):151–157.
   PubMed Web of Science ®Google Scholar
• Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol. 2011 Mar;13(3):317–323.
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Cohen KJ, Buxton A, et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423 study. Neuro Oncol. 2016;18(10):1442–1450.
   PubMed Web of Science ®Google Scholar
• Hayden E, Holliday H, Lehmann R, et al. Therapeutic targets in diffuse midline gliomas-an emerging landscape. Cancers (Basel). 2021 Dec 13;13(24):6251.
   PubMed Web of Science ®Google Scholar
• Bredlau AL, Korones DN. Diffuse intrinsic pontine gliomas: treatments and controversies. Adv Cancer Res. 2014;121:235–259.
   PubMed Web of Science ®Google Scholar
• Frazier JL, Lee J, Thomale UW, et al. Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr. 2009 Apr;3(4):259–269.
   PubMed Web of Science ®Google Scholar
• Jalali R, Raut N, Arora B, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):113–118.
   PubMed Web of Science ®Google Scholar
• Aziz-Bose R, Monje M. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets. Curr Opin Oncol. 2019 Nov;31(6):522–530.
   PubMed Web of Science ®Google Scholar
• Patel DH, Misra A. 5 - Gene delivery using viral vectors. Challenges in delivery of therapeutic genomics and proteomics. A. Misra. London: Elsevier Inc.; 2011. p. 207–270.
   Google Scholar
• Bin Umair M, Akusa FN, Kashif H, et al. Viruses as tools in gene therapy, vaccine development, and cancer treatment. Arch Virol. 2022 Jun;167(6):1387–1404.
   PubMed Web of Science ®Google Scholar
• Lee CS, Bishop ES, Zhang R, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017 Jun;4(2):43–63.
   PubMed Web of Science ®Google Scholar
• Ji N, Weng D, Liu C, et al. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget. 2016 Jan 26;7(4):4369–4378.
   PubMedGoogle Scholar
• Wheeler LA, Manzanera AG, Bell SD, et al. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro Oncol. 2016 Aug;18(8):1137–1145.
   PubMed Web of Science ®Google Scholar
• Kieran MW, Goumnerova L, Manley P, et al. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro Oncol. 2019 Mar 18;21(4):537–546.
   PubMed Web of Science ®Google Scholar
• Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21(13):2508–2518.
   PubMed Web of Science ®Google Scholar
• Barrett JA, Cai H, Miao J, et al. Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System(®) (RTS(®)) gene switch as gene therapy for the treatment of glioma. Cancer Gene Ther. 2018 Jun;25(5–6):106–116.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Yu JS, Lukas RV, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci Transl Med. 2019 Aug 14;11(505):eaaw5680.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Gelb AB, Chen CC, et al. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase I trial. Neuro Oncol. 2022 Jun 1;24(6):951–963.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Smith KM, McKinney B, et al. A phase I trial of Ad.hIFN-β gene therapy for glioma. Mol Ther. 2008 March 01;16(3):618–626.
   PubMed Web of Science ®Google Scholar
• Gruslova A, Cavazos DA, Miller JR, et al. VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme. J Neurooncol. 2015 Sep;124(3):365–372.
   PubMed Web of Science ®Google Scholar
• Brenner AJ, Cohen YC, Vredenburgh JJ, et al. Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: a phase 2 historically controlled trial. J Clin Oncol. 2016;34(15_suppl):2074.
   Web of Science ®Google Scholar
• Cloughesy TF, Petrecca K, Walbert T, et al. Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial. JAMA Oncol. 2020 Dec 1;6(12):1939–1946.
   PubMed Web of Science ®Google Scholar
• Ghajar-Rahimi G, Kang KD, Totsch SK, et al. Clinical advances in oncolytic virotherapy for pediatric brain tumors. Pharmacol Ther. 2022 Apr 26;239:108193.
   PubMed Web of Science ®Google Scholar
• Kiyokawa J, Wakimoto H. Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma. Oncolytic Virother. 2019;8:27–37.
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000 Jan 6;19(1):2–12.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018 May 10;36(14):1419–1427.
   PubMed Web of Science ®Google Scholar
• van den Bossche WBL, Kleijn A, Teunissen CE, et al. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. Neuro Oncol. 2018 Oct 9;20(11):1494–1504.
   PubMed Web of Science ®Google Scholar
• Lang FF, Tran ND, Puduvalli VK, et al. Phase 1b open-label randomized study of the oncolytic adenovirus DNX-2401 administered with or without interferon gamma for recurrent glioblastoma. J Clin Oncol. 2017;35(15_suppl):2002.
   Google Scholar
• Wilcox DR, Longnecker R. The herpes simplex virus neurovirulence factor γ34.5: revealing virus-host interactions. PLoS Pathog. 2016 Mar;12(3):e1005449.
   PubMed Web of Science ®Google Scholar
• Alayo QA, Ito H, Passaro C, et al. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. Sci Rep. 2020 Mar 20;10(1):5095.
   PubMed Web of Science ®Google Scholar
• Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991 May 10;252(5007):854–856.
   PubMed Web of Science ®Google Scholar
• Markert JM, Razdan SN, Kuo HC, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014 May;22(5):1048–1055.
   PubMed Web of Science ®Google Scholar
• Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2009 Jan;17(1):199–207.
   PubMed Web of Science ®Google Scholar
• Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000 May;7(10):867–874.
   PubMed Web of Science ®Google Scholar
• Friedman GK, Johnston JM, Bag AK, et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med. 2021 Apr 29;384(17):1613–1622.
   PubMed Web of Science ®Google Scholar
• Patel DM, Foreman PM, Nabors LB, et al. Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Hum Gene Ther Clin Dev. 2016;27(2):69–78.
   PubMed Web of Science ®Google Scholar
• Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396–6401.
   PubMed Web of Science ®Google Scholar
• Todo T, Ito H, Ino Y, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022 August 01;28(8):1630–1639.
   PubMedGoogle Scholar
• Chiocca EA, Nakashima H, Kasai K, et al. Preclinical toxicology of rQNestin34.5v.2: an oncolytic herpes virus with transcriptional regulation of the ICP34.5 neurovirulence gene. Mol Ther Methods Clin Dev. 2020 Jun 12;17:871–893.
   PubMed Web of Science ®Google Scholar
• Otani Y, Yoo JY, Lewis CT, et al. NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy. Clin Cancer Res. 2022 Apr 1;28(7):1460–1473.
   PubMed Web of Science ®Google Scholar
• Goff SP. Genetics of retroviral integration. Annu Rev Genet. 1992;26:527–544.
   PubMed Web of Science ®Google Scholar
• Tai CK, Kasahara N. Replication-competent retrovirus vectors for cancer gene therapy. Front Biosci. 2008 Jan 1;13:3083–3095.
   PubMed Web of Science ®Google Scholar
• Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000 Nov 20;11(17):2389–2401.
   PubMed Web of Science ®Google Scholar
• Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997 Dec;3(12):1354–1361.
   PubMed Web of Science ®Google Scholar
• Klatzmann D, Valéry CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Hum Gene Ther. 1998 November 20;9(17):2595–2604.
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May 01;3(5):330–338.
   PubMed Web of Science ®Google Scholar
• Huang TT, Hlavaty J, Ostertag D, et al. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Cancer Gene Ther. 2013 Oct;20(10):544–551.
   PubMed Web of Science ®Google Scholar
• Ostertag D, Amundson KK, Lopez Espinoza F, et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol. 2012 Feb;14(2):145–159.
   PubMed Web of Science ®Google Scholar
• Tai CK, Wang WJ, Chen TC, et al. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther. 2005 Nov;12(5):842–851.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Valdes G, Hiraoka K, et al. Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. Cancer Gene Ther. 2014 Oct;21(10):405–410.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Landolfi J, Vogelbaum MA, et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018 Sep 3;20(10):1383–1392.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, van Gool S, Stuecker W. Breaking therapy resistance: an update on oncolytic Newcastle disease virus for improvements of cancer therapy. Biomedicines. 2019 Aug 30;7(3):66.
   PubMed Web of Science ®Google Scholar
• Vigil A, Park MS, Martinez O, et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 2007 Sep 1;67(17):8285–8292.
   PubMed Web of Science ®Google Scholar
• Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2006 Jan;13(1):221–228.
   PubMed Web of Science ®Google Scholar
• Dorig RE, Marcil A, Chopra A, et al. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993 Oct 22;75(2):295–305.
   PubMed Web of Science ®Google Scholar
• Muhlebach MD, Mateo M, Sinn PL, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature. 2011 Nov 2;480(7378):530–533.
   PubMed Web of Science ®Google Scholar
• Galanis E, Bateman A, Johnson K, et al. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther. 2001 May 1;12(7):811–821.
   PubMed Web of Science ®Google Scholar
• Msaouel P, Opyrchal M, Domingo Musibay E, et al. Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther. 2013 Apr;13(4):483–502.
   PubMed Web of Science ®Google Scholar
• Estevez-Ordonez D, Chagoya G, Salehani A, et al. Immunovirotherapy for the treatment of glioblastoma and other malignant gliomas. Neurosurg Clin N Am. 2021 Apr;32(2):265–281.
   PubMed Web of Science ®Google Scholar
• Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998;17(12):3351–3362.
   PubMed Web of Science ®Google Scholar
• Forsyth P, Roldán G, George D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther. 2008 Mar;16(3):627–632.
   PubMed Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med. 2018 Jul 12;379(2):150–161.
   PubMed Web of Science ®Google Scholar
• Herrero YCM, Cornelis JJ, Herold-Mende C, et al. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer. 2004 Mar;109(1):76–84.
   PubMed Web of Science ®Google Scholar
• Geletneky K, Huesing J, Rommelaere J, et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: parvOryx01 protocol. BMC Cancer. 2012 Mar 21;12:99.
   PubMed Web of Science ®Google Scholar
• Haddad D. Genetically engineered vaccinia viruses as agents for cancer treatment, imaging, and transgene delivery [Review]. Front Oncol. 2017 May 23; 7. DOI:10.3389/fonc.2017.00096.
   Web of Science ®Google Scholar
• Béguin J, Foloppe J, Maurey C, et al. Preclinical evaluation of the oncolytic vaccinia virus TG6002 by translational research on canine breast cancer. Molecular Therapy - Oncolytics. 2020 December 16;19:57–66.
   PubMed Web of Science ®Google Scholar
• Foloppe J, Kempf J, Futin N, et al. The enhanced tumor specificity of TG6002, an armed oncolytic vaccinia virus deleted in two genes involved in nucleotide metabolism. Molecular Therapy - Oncolytics. 2019 September 27;14:1–14.
   PubMed Web of Science ®Google Scholar
• Del Vecchio C, Calistri A, Parolin C, et al. Lentiviral vectors as tools for the study and treatment of glioblastoma. Cancers (Basel). 2019 Mar 24;11(3):417.
   PubMed Web of Science ®Google Scholar
• Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet. 2011 May;12(5):316–328.
   PubMed Web of Science ®Google Scholar
• Kumar M, Keller B, Makalou N, et al. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther. 2001 Oct 10;12(15):1893–1905.
   PubMed Web of Science ®Google Scholar
• Miletic H, Fischer YH, Neumann H, et al. Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. Hum Gene Ther. 2004 Nov;15(11):1091–1100.
   PubMed Web of Science ®Google Scholar
• Huszthy PC, Giroglou T, Tsinkalovsky O, et al. Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One. 2009 Jul 20;4(7):e6314.
   PubMed Web of Science ®Google Scholar
• Luan Y, Zhang S, Zuo L, et al. Overexpression of miR-100 inhibits cell proliferation, migration, and chemosensitivity in human glioblastoma through FGFR3. Onco Targets Ther. 2015;8:3391–3400.
   PubMed Web of Science ®Google Scholar
• Yu S, Li A, Liu Q, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017 Mar 29;10(1):78.
   PubMed Web of Science ®Google Scholar
• Sanchez-Hernandez L, Hernandez-Soto J, Vergara P, et al. Additive effects of the combined expression of soluble forms of GAS1 and PTEN inhibiting glioblastoma growth. Gene Ther. 2018 Sep;25(6):439–449.
   PubMed Web of Science ®Google Scholar
• Tome-Garcia J, Erfani P, Nudelman G, et al. Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma. Nat Commun. 2018 Oct 1;9(1):4020.
   PubMedGoogle Scholar
• Scherr M, Venturini L, Battmer K, et al. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 2007;35(22):e149.
   PubMed Web of Science ®Google Scholar
• Sun BS, Dong QZ, Ye QH, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008 Dec;48(6):1834–1842.
   PubMed Web of Science ®Google Scholar
• Zeng LL, He XS, Liu JR, et al. Lentivirus-mediated overexpression of MicroRNA-210 improves long-term outcomes after focal cerebral ischemia in mice. CNS Neurosci Ther. 2016 Dec;22(12):961–969.
   PubMed Web of Science ®Google Scholar
• Scherr M, Venturini L, Eder M. Lentiviral vector-mediated expression of pre-miRNAs and antagomiRs. Methods Mol Biol. 2010;614:175–185.
   PubMedGoogle Scholar
• Song JL, Zheng W, Chen W, et al. Lentivirus-mediated microRNA-124 gene-modified bone marrow mesenchymal stem cell transplantation promotes the repair of spinal cord injury in rats. Exp Mol Med. 2017 May 19;49(5):e332.
   PubMedGoogle Scholar
• Alt EU, Barabadi Z, Pfnur A, et al. TRAF3IP2, a novel therapeutic target in glioblastoma multiforme. Oncotarget. 2018 Jul 3;9(51):29772–29788.
   PubMedGoogle Scholar
• Szabo E, Schneider H, Seystahl K, et al. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. Neuro Oncol. 2016 Sep;18(9):1242–1252.
   PubMed Web of Science ®Google Scholar
• Li C, Bowles DE, van Dyke T, et al. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 2005 Dec;12(12):913–925.
   PubMed Web of Science ®Google Scholar
• Stilwell JL, Samulski RJ. Adeno-associated virus vectors for therapeutic gene transfer. Biotechniques. 2003 Jan;34(1):148–150.
   PubMed Web of Science ®Google Scholar
• McCown TJ. Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther. 2005 Jun;5(3):333–338.
   PubMed Web of Science ®Google Scholar
• van Putten EH, Dirven CM, van den Bent MJ, et al. Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol. 2010 Nov;6(11):1691–1710.
   PubMed Web of Science ®Google Scholar
• Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release. 2016 Oct 28;240:287–301.
   PubMed Web of Science ®Google Scholar
• Enger PO, Thorsen F, Lonning PE, et al. Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Hum Gene Ther. 2002 Jun 10;13(9):1115–1125.
   PubMed Web of Science ®Google Scholar
• Maier P, von Kalle C, Laufs S. Retroviral vectors for gene therapy. Future Microbiol. 2010 Oct;5(10):1507–1523.
   PubMed Web of Science ®Google Scholar
• Asad AS, Moreno Ayala MA, Gottardo MF, et al. Viral gene therapy for breast cancer: progress and challenges. Expert Opin Biol Ther. 2017 Aug;17(8):945–959.
   PubMed Web of Science ®Google Scholar
• Riyad JM, Weber T. Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Ther. 2021 Dec;28(12):683–696.
   PubMed Web of Science ®Google Scholar
• GuhaSarkar D, Neiswender J, Su Q, et al. Intracranial AAV-IFN-beta gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model. Mol Oncol. 2017 Feb;11(2):180–193.
   PubMed Web of Science ®Google Scholar
• Yoshida J, Mizuno M, Nakahara N, et al. Antitumor effect of an adeno-associated virus vector containing the human interferon-beta gene on experimental intracranial human glioma. Jpn J Cancer Res. 2002 Feb;93(2):223–228.
   PubMedGoogle Scholar
• Crommentuijn MH, Maguire CA, Niers JM, et al. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. Mol Oncol. 2016 Apr;10(4):625–634.
   PubMed Web of Science ®Google Scholar
• Yao Y, Wang J, Liu Y, et al. Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates. Nat Biomed Eng. 2022 Nov;6(11):1257–1271.
   Web of Science ®Google Scholar
• van Oers MM, Pijlman GP, Vlak JM. Thirty years of baculovirus-insect cell protein expression: from dark horse to mainstream technology. J Gen Virol. 2015 Jan;96(Pt 1):6–23.
   PubMedGoogle Scholar
• Dautzenberg IJC, van den Hengel SK, de Vrij J, et al. Baculovirus-assisted reovirus infection in monolayer and spheroid cultures of glioma cells. Sci Rep. 2017 Dec 15;7(1):17654.
   PubMedGoogle Scholar
• Ang WX, Zhao Y, Kwang T, et al. Local immune stimulation by intravesical instillation of baculovirus to enable bladder cancer therapy. Sci Rep. 2016 Jun 8;6:27455.
   PubMed Web of Science ®Google Scholar
• Wang CY, Li F, Yang Y, et al. Recombinant baculovirus containing the diphtheria toxin A gene for malignant glioma therapy. Cancer Res. 2006 Jun 1;66(11):5798–5806.
   PubMed Web of Science ®Google Scholar
• Caffery B, Lee JS, Alexander-Bryant AA. Vectors for glioblastoma gene therapy: viral & non-viral delivery strategies. Nanomaterials (Basel). 2019 Jan 16;9(1):105.
   PubMedGoogle Scholar
• Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009 Nov;30(11):592–599.
   PubMed Web of Science ®Google Scholar
• Wiwatchaitawee K, Quarterman JC, Geary SM, et al. Enhancement of therapies for glioblastoma (GBM) using nanoparticle-based delivery systems. AAPS PharmSciTech. 2021 Feb 11;22(2):71.
   PubMed Web of Science ®Google Scholar
• Senzer N, Nemunaitis J, Nemunaitis D, et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther. 2013 May;21(5):1096–1103.
   PubMed Web of Science ®Google Scholar
• Kim SS, Rait A, Kim E, et al. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine. 2015 Feb;11(2):301–311.
   PubMed Web of Science ®Google Scholar
• Kumthekar P, Ko CH, Paunesku T, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021 Mar 10;13(584):eabb3945.
   PubMed Web of Science ®Google Scholar
• Gregory JV, Kadiyala P, Doherty R, et al. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun. 2020 Nov 10;11(1):5687.
   PubMed Web of Science ®Google Scholar
• Prentice DA. Adult Stem Cells. Circ Res. 2019;124(6):837–839.
   PubMed Web of Science ®Google Scholar
• Clevers H. What is an adult stem cell? Science. 2015;350(6266):1319–1320.
   PubMed Web of Science ®Google Scholar
• Seita J, Weissman IL. Hematopoietic stem cell: self‐renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2(6):640–653.
   PubMed Web of Science ®Google Scholar
• Gage FH. Mammalian neural stem cells. Science. 2000 Feb 25;287(5457):1433–1438.
   PubMed Web of Science ®Google Scholar
• Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846–12851.
   PubMed Web of Science ®Google Scholar
• Bechmann I, Galea I, Perry VH. What is the blood–brain barrier (not)? Trends Immunol. 2007 January 01;28(1):5–11.
   PubMed Web of Science ®Google Scholar
• Spaeth E, Klopp A, Dembinski J, et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008 May 01;15(10):730–738.
   PubMed Web of Science ®Google Scholar
• Carey-Ewend AG, Hagler SB, Bomba HN, et al. Developing bioinspired three-dimensional models of brain cancer to evaluate tumor-homing neural stem cell therapy. Tissue Eng Part A. 2021 Jul;27(13–14):857–866.
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Tumors: wounds that do not heal. N Engl J Med. 1986;315(26):1650–1659.
   PubMed Web of Science ®Google Scholar
• Müller F-J, Snyder EY, Loring JF. Gene therapy: can neural stem cells deliver? Nat Rev Neurosci. 2006 January 01;7(1):75–84.
   PubMed Web of Science ®Google Scholar
• Jung Y, Kim JK, Shiozawa Y, et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun. 2013 April 30;4(1):1795.
   PubMedGoogle Scholar
• Rattigan Y, Hsu J-M, Mishra PJ, et al. Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp Cell Res. 2010 December 10;316(20):3417–3424.
   PubMed Web of Science ®Google Scholar
• Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood. 2012;120(15):3142–3151.
   PubMed Web of Science ®Google Scholar
• Stuckey DW, Shah K. Stem cell-based therapies for cancer treatment: separating hope from hype. Nat Rev Cancer. 2014 October 01;14(10):683–691.
   PubMed Web of Science ®Google Scholar
• Magge SN, Malik SZ, Royo NC, et al. Role of monocyte chemoattractant protein-1 (MCP-1/CCL2) in migration of neural progenitor cells toward glial tumors. J Neurosci Res. 2009;87(7):1547–1555.
   PubMed Web of Science ®Google Scholar
• Molina-Holgado E, Molina-Holgado F. Mending the broken brain: neuroimmune interactions in neurogenesis. J Neurochem. 2010;114(5):1277–1290.
   PubMed Web of Science ®Google Scholar
• Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Nat Acad Sci. 2009;106(12):4822–4827.
   PubMed Web of Science ®Google Scholar
• Hingtgen SD, Kasmieh R, van de Water J, et al. A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. Stem Cells. 2010;28(4):832–841.
   PubMed Web of Science ®Google Scholar
• Menon LG, Kelly K, Yang HW, et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells. 2009;27(9):2320–2330.
   PubMed Web of Science ®Google Scholar
• Kauer TM, Figueiredo J-L, Hingtgen S, et al. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci. 2012 February 01;15(2):197–204.
   Web of Science ®Google Scholar
• Balyasnikova IV, Ferguson SD, Han Y, et al. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett. 2011 November 28;310(2):148–159.
   PubMed Web of Science ®Google Scholar
• Gutova M, Goldstein L, Metz M, et al. Optimization of a neural stem-cell-mediated carboxylesterase/irinotecan gene therapy for metastatic neuroblastoma. Mol Ther Oncolytics. 2017 Mar 17;4:67–76.
   PubMed Web of Science ®Google Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–1826.
   PubMed Web of Science ®Google Scholar
• Portnow J, Synold TW, Badie B, et al. Neural stem cell–based anticancer gene therapy: a first-in-human study in recurrent high-grade glioma patients. Clin Cancer Res. 2017;23(12):2951–2960.
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Ulasov IV, Tyler MA, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells. 2008;26(3):831–841.
   PubMed Web of Science ®Google Scholar
• Fares J, Ahmed AU, Ulasov IV, et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol. 2021 August 01;22(8):1103–1114.
   PubMed Web of Science ®Google Scholar
• Sloan AE, Roger L, Murphy C, et al. A phase I study of MGMT-P140K transfected hematopoietic progenitor cells (HPC) combined with TMZ/O6BG dose escalation for newly diagnosed, MGMT unmethylated glioblastoma: tolerance and evidence of survival benefit. J Clin Oncol. 2019;37(15_suppl):2062.
   PubMed Web of Science ®Google Scholar